Marco Peters

Dr. Peters has over 20 years of experience in translational research, target discovery, and small molecule discovery for CNS indications. Dr. Peters built and managed small and large research teams, and his work has contributed to the discovery, progression, and clinical development of small molecule therapeutics for the treatment of multiple neurological indications including stroke, Parkinson’s disease, Pain, and Schizophrenia. Prior to joining Longboard, he served as the Senior Director of Research and Development at BioIntervene, Inc., where he led preclinical research and developed biomarker strategies for non-addictive, non-opioid, treatments for pain. Prior to BioIntervene, Dr. Peters held positions of increasing responsibility at Dart Neuroscience, where he built the departments of Neurobiology and Behavioral Pharmacology, and managed target ID, in vivo pharmacology, and lead optimization. His work at Dart contributed to the advancement of multiple compounds into clinical development, and a broad intellectual property portfolio. Dr. Peters holds a Ph.D. in Neuroscience from the University of London, UK, and an M.Sc. in Biochemistry with distinction from the Freie Universität Berlin, Germany. He conducted post-doctoral work with Tetsuyuki Maruyama at Merck Sharp & Dohme (UK).